Drug PotentialALXN1840 is considered a derisked drug for the treatment of Wilson's disease, which may lead to regulatory approval and future revenue.
Market SizeThe total addressable market for ALXN1840 could reach $420M in the U.S. alone, based on an estimate of 10,000-12,000 WD patients in the U.S.
Therapeutic ProgressMNPR-101 continues to make progress, with the company initiating a first-in-human Phase 1 study of MNPR-101-Lu for the treatment of advanced solid tumors.